Spleen volume change as a prognostic and immunologic imaging biomarker in extensive-stage small-cell lung cancer receiving chemo-immunotherapy
SV change reflects both local and systemic immune remodeling during CIT in ES-SCLC. As a noninvasive and measurable imaging biomarker, SV change holds translational potential for immune monitoring and treatment response assessment.
Authors
- Yi Li (ORCID: https://orcid.org/0000-0001-6389-7888)
- Jiazhong Ren
- Shuqing Duan
- Mingdong Li (ORCID: https://orcid.org/0000-0001-8186-6735)
- Xiuli Liu (ORCID: https://orcid.org/0000-0003-4936-2179)
- Zhichao Li
- Defeng Liu
- Yuanlin Li
- Jinming Yu
- Ao Liu
Institutions
- Shandong University (CN)
- Shandong Tumor Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/17588359261417776
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00